Johnson & Johnson Receives Approval for Subcutaneous Amivantamab Injection: A Breakthrough for NSCLC Patients Johnson & Johnson's subcutaneous amivantamab injection approval marks a significant milestone in treating EGFR mutation-positive NSCLC, with improved efficacy.

Johnson & Johnson Receives Approval for Subcutaneous Amivantamab Injection: A Breakthrough for NSCLC Patients #Japan #Tokyo #NSCLC #EGFR_Mutation #Amivantamab

Lunit and AstraZeneca Unveil Groundbreaking AI for Cancer Genotyping at AACR 2025 Lunit will present an innovative AI study predicting EGFR mutations in NSCLC at AACR 2025, showcasing the potential of AI to enhance cancer diagnostics.

Lunit and AstraZeneca Unveil Groundbreaking AI for Cancer Genotyping at AACR 2025 #South_Korea #Seoul #AstraZeneca #Lunit #EGFR_Mutation